Previous 10 | Next 10 |
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference as follows: The present...
The following slide deck was published by Eagle Pharmaceuticals, Inc. in conjunction with this Read more ...
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2019 RBC Capital Markets Global Healthcare Conference as follows: T...
Eagle Pharmaceuticals, Inc. (EGRX) Q1 2019 Earnings Conference Call May 7, 2019, 08:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - Founder and CEO David Pernock - President and Chief Commercial Officer Pete Meyers - CFO, Principal Financial Officer and Principal...
Eagle Pharmaceuticals ( EGRX +2.7% ) is up, albeit on below-average volume, in response to positive results from a study conducted with the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) that demonstrated the neuroprotective effects of RYANODEX (dantrolene sodium) af...
Eagle Pharmaceuticals (NASDAQ: EGRX ): Q1 Non-GAAP EPS of $1.01 beats by $0.28 ; GAAP EPS of $0.62. More news on: Eagle Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Q1 2019 net income of $0.64 per basic and $0.62 per diluted share and adjusted non-GAAP net income of $1.05 per basic and $1.01 per diluted share -- -- Revised licensing agreement for BENDEKA ® extends term of contract and increases royalty rate to 32% in 2021 -- -- CMS issu...
-- Statistically significant lower incidence of brain damage compared to control group, demonstrating neuroprotective properties of RYANODEX in treating nerve agent exposure -- -- Statistically significant robust p-values of 0.04 or less were determined in six cortical areas of the brain ...
ADNT , AES , AGN , AKRX , AMAG , ARMK , ARRY , ATH , ATKR , AVNS , BCC , BGCP , BLD , BR , BUD , CJ , CLVS , CNHI , CNK , CRL , CROX , CTLT , CWEN , DEA , DF , DNR , DPLO , DXPE , EGRX , EMR , ENR , EXPD , FI , GSKY , GTE , GTX , HAE , HSIC , ICL , IM...
Eagle Pharmaceuticals, Inc. ("Eagle" or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2019 first quarter financial results on Tuesday, May 7, 2019, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Fina...
News, Short Squeeze, Breakout and More Instantly...
Eagle Pharmaceuticals Inc. Company Name:
EGRX Stock Symbol:
NASDAQ Market:
Eagle Pharmaceuticals Inc. Website:
2024-07-27 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-17 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-07 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...